Arcellx Inc (ACLX)vsAlnylam Pharmaceuticals Inc (ALNY)
ACLX
Arcellx Inc
$114.54
-0.13%
HEALTHCARE · Cap: $6.71B
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 16565% more annual revenue ($3.71B vs $22.29M). ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ACLX
Avoid22
out of 100
Grade: F
ALNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACLX.
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Areas to Watch
Trading at 16.5x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ACLX
ACLX has a balanced fundamental profile.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bear Case : ACLX
The primary concerns for ACLX are Price/Book, EPS Growth, Profit Margin.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Key Dynamics to Monitor
ACLX profiles as a value stock while ALNY is a hypergrowth play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.38 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 22/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arcellx Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arcellx, Inc., a clinical-stage biotechnology company, is engaged in the development of various immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Gaithersburg, Maryland.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?